Ribosomes: The future of targeted therapies?

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1554-1555

  Marcel, Virginie ^a,b   Catez, Frédéric ^a,b   Diaz, Jean Jacques ^a,b  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CX 5461; FIBRILLARIN; RIBOSOME PROTEIN; RIBOSOME RNA; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RNA METHYLATION; RNA STRUCTURE; TRANSLATION REGULATION;

ANTINEOPLASTIC AGENTS; HUMANS; RIBOSOMES; RNA, RIBOSOMAL;

EID: 84886732942     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1511     Document Type: Article

References (8)

1. Drygin et al. Cancer Research. 2011; 71:1418-1430.
2. Bywater et al. Cancer Cell. 2012; 22: 51-65.
3. Ruggero. Cold Spring Harb Persp Biol. 2013 ; 5:a012336.
4. Belin et al. Plos One. 2009; 4:e7147.
5. Marcel et al. Cancer Cell. 2013; 24(3):318-330.
6. Bidou et al. Trends Mol Med. 2012; 18:679-688.
7. Su et al. Oncogene. 2013; doi: 10.1038/onc.2013.89.
8. Silvera et al. Nat Rew Cancer. 2010; 10:254-266.